Opendata, web and dolomites

NIRCOThera SIGNED

Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NIRCOThera project word cloud

Explore the words cloud of the NIRCOThera project. It provides you a very rough idea of what is the project "NIRCOThera" about.

therapeutic    precise    loaded    intratumoural    followed    reported    unexploited    body    microenvironment    fast    tumours    site    species    impart    walled    strategy    manipulate    reactive    clearance    activation    corms    ultrahigh    rebr3    herein    consists    chemotherapeutics    health    nir    shown    components    ros    spatiotemporal    release    profile    chosen    inflammation    disorders    rhenium    platform    exogeneous    triggered    models    infiltrating    purpose    expression    precision    toxicity    excretion    cells    plan    effect    cell    metastasis    treatment    light    releasing    nanotubes    avenue    critical    signaling    co    anti    time       animal    inflammatory    lipid    chemotherapy    bifunctional    cardiovascular    functionalized    vivo    cancer    exposure    tissues    net4    eradicate    expecting    genes    oxygen    immune    ready    diseases    protein    tumour    combine    near    relatively    sites    conjugate    stability    realize    dependent    naturally    modulatory    immunomodulatory    sensitivity    infrared    progression    multiple    single    largely    human    carbon    molecules    angiogenesis       gaseous    exclusively    progress    generation    manner    molecule    biocompatibility    monoxide    dose    swcnts   

Project "NIRCOThera" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Carbon monoxide (CO) is a gaseous signaling molecule naturally produced by the human body. In recent years, CO has shown its anti-inflammatory and immunomodulatory properties and thus therapeutic potential in the treatment of inflammatory disorders and cardiovascular diseases. It is promising to exploit the modulatory effect of exogeneous CO in tumour microenvironment where inflammation and angiogenesis are the critical components of tumour progression and metastasis, which is largely unexploited. For this purpose, it is key to manipulate CO exposure in a precise dose and time-controlled manner exclusively at the tumour site. Herein, we propose to develop a new CO delivery avenue, enabling controlled CO release to tumour sites with spatiotemporal precision by using near infrared light (NIR). Specifically, the strategy consists of single-walled carbon nanotubes (SWCNTs) loaded with CO releasing molecules (CORMs). We have reported the development of a SWCNTs-based bifunctional system that enables intratumoural protein delivery and NIR activation, which is ready to be applied to realize controlled CO release in vivo. We plan to conjugate [ReBr3(CO)3][NEt4]2 to SWCNTs. The rhenium complex is chosen because of its stability and non-toxicity while the lipid functionalized SWCNTs have shown biocompatibility, ultrahigh tumour uptake and relatively fast clearance and excretion from the health tissues, which impart the platform promising for in vivo application. We will evaluate the stability of the platform, followed by the NIR-triggered CO release profile and then dose- and time-dependent effect on both cancer cells and tumour-infiltrating immune cells, including the generation of reactive oxygen species (ROS) and expression of multiple genes associated with tumour progress. Furthermore, expecting increased cancer cell sensitivity to chemotherapeutics with CO treatment, we will combine the proposed strategy with current chemotherapy to eradicate tumours in animal models.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NIRCOTHERA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NIRCOTHERA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ParkIFNAR (2020)

Soluble IFNAR2 in Parkinson's disease and its role in the regulation of IFNβ in a neuroinflammatory context.

Read More  

GENESIS (2020)

unveilinG cEll-cell fusioN mEdiated by fuSexins In chordateS

Read More  

ROAR (2019)

Investigating the Role of Attention in Reading

Read More